VC: Therion raises $30 million



Therion raises $30 million in fourth round.

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Therion Biologics
Cambridge, MA

$30M
fourth

Hans-Werner Hector

The funds will go to the clinical development of PanVac-VF and ProstVaC-VF, its lead product candidates to treat pancreatic cancer and prostate cancer.

ProMetic Life Sciences
Montreal

$15M
undisclosed

Sprott Securities

ProMetic has been developing treatments for cancer and inflammation/autoimmune diseases.

Exagen Diagnostics
Albuquerque, NM

$7M
second

Tullis-Dickerson & Co

Exagen is developing genomic market IVD kits for breast cancer.

AmpliMed Corp
Tucson, AZ

$5M
two

Biotech Insight Ventures

The money will go to expand its pipeline of cancer drugs and push new clinical trials.

TriMed Research
Omaha, NE

$5M
one

Inventages venture capital investments

TriMed is beginning to develop therapies based on research related to the mammary gland protein designated as MAA.